Debiopharm and Aurigene collaborate on Debio 1142; Xention and Ono extend accord

Swiss independent drug developer Debiopharm and Aurigene Discovery Technologies, a Bangalore, India-based drug discovery company, have signed an option and exclusive worldwide license agreement concerning the development and commercialization of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.

"We are very excited about this new collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimisation and preclinical work. The Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours, including resistance to chemotherapy" said Rolland-Yves Mauvernay, president and founder of Debiopharm.

"Coming as it does after a successful collaboration program we already had with Debiopharm, and as a continuation of our close to five-year association, the relationship between Debiopharm and Aurigene demonstrates the strategic fit between organizations with complimentary scientific skills. We are happy that we have the opportunity to continue to work with Debiopharm, in a unique business model that has been tailor-made to meet each partners' needs" added CSN Murthy, chief executive of Aurigene.